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1. Introduction 
The rate of synthesis of rat liver cytosolic P-enol- 
pyruvate carboxykinase (GTP), a key gluconeogenic 
enzyme, rapidly decreases upon glucose feeding to 
fasted rats [ 1,2] or insulin injection to diabetic rats 
[2]. A corresponding decrease in translatable P-enol- 
pyruvate carboxykinase mRNA occurs upon refeeding 
[3]. However, it appears that the decay of the poly- 
somal mRNA for the enzyme occurs at a slower rate 
than that of total enzyme mRNA [3]. This suggests 
that during deinduction either the polysomal mRNA 
is selectively protected from degradation or there is a 
shift of the enzyme’s mRNA into polysomes. 
Experiments using a protein synthesis (run off) 
system from liver postmitochondrial supernatants 
show that a transient increase (30 min) in the syn- 
thesis of the enzyme occurs after glucose is tube-fed 
to fasted rats or insulin given to diabetic rats [4]. This 
results from an increase in polysomal P-enolpyruvate 
carboxykinase mRNA without a change in total trans- 
latable activity for the enzyme, constituting a 
transient increase in translational efficiency [4]. Thus, 
by being shifted into the polysomzs, the mRNA for 
P-enolpyruvate carboxykinase may be relatively pro- 
tected from degradation. 
To examine whether non-polysomal mRNA for 
P-enolpyruvate carboxykinase is preferentially 
degraded, we have now used inhibitors of protein 
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synthesis to create dissociation of polysomes (pacta- 
mycin) and polysomal aggregation (cycloheximide). 
However, we have found that irrespective of the poly- 
somal state, either of these inhibitors given together 
with insulin abolished the hormone’s effect. Further 
elaboration of this finding and its implication will be 
described. 
2. Materials and methods 
2.1. Materials 
Alloxan monohydrate, cycloheximide, heparin, 
cordycepin and Hepes were purchased from Sigma 
Chemical Co. Pactamycin was from Upjohn Co. Insulin 
(glucagon-free) was a gift of Eli Lilly Co. SDS from 
BDH was recrystallized. 8-OH-Quinolinate was from 
Merck. Oligo-(dT) cellulose type III was from Colla- 
borative Research Inc. (Waltham, MA). L-[4,5-3H] - 
Leucine (30 Ci/mmol) was from Nuclear Research 
Center (Negev, Israel). NCS tissue solubilizer was 
from Amersham Searle Corp. The wheat germ used 
was a gift from General Mills, Inc. 
2.2. Treatment of animals 
Week 7 albino Sabra rats from the Hebrew Uni- 
versity Breeding Center, were rendered diabetic by a 
19 mg/lOO g body wt subcutaneous injection of 
alloxan and used 447 days later based on positive 
glucosuria. Interperitoneal injections of insulin 
(5 U/100 g), cycloheximide (0.1 mg/lOO g), pacta- 
mycin (0.3 mg/ 100 g) or cordycepin (1.5 mg/ 100 g) 
were given at the times indicated. All rats were tube 
fed with glucose 0.5 g/100 g body wt 90 min prior to 
sacrifice to ensure and standardize hyperglyceinia. 
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2.3. Preparation of polysome profiles 
This was done as in [4]. 
2.4. Kate of protein sy~~thesis 
This was determined in vivo according to [S] by 
injecting 12 &i/l00 g body wt [3H]leucine to rats 
20 min before sacrifice. 
Isolation of poly(A)+ RNA from postmitochon- 
drial liver supernatants 143, translation in wheat germ 
lysates and determination of P-enolpyruvate carboxy- 
kinase mRNA translatable activity, were performed 
as in [3,6,7]. Preparation of wheat germ lysates was 
as in [8,9]. 
3. Results 0.1 
3.1. Effect of insulin, pactamycin and cycloheximide 
on n’bosomal aggregation and protein synthesis 
It has been shown that short-term glucose feeding 
to fasted rats ]4,10,1 I ] or insulin treatment to dia- 
betic rats [ 121 caused an aggregation of ribosomes 
with a corresponding decrease in monosome and sub- 
unit concentration [S ,lO,l I 1. Our recording of poly- 
some profiles confirmed this finding (fig.lA), demon- 
strating that insulin injection to diabetic rats for 90 
min caused a shift to heavier polysomes, with a corre- 
sponding decrease in small polysomes, monosomes 
and subunits, 
Pactamycin, an inhibitor of initiation of protein 
synthesis [13-l S]was used to degrade polysornes. 
When injected intraperitoneally (0.3 mg/lOO g body 
wt) 30 min prior to insulin treatment, it caused an 
almost complete dissociation of polysomes (fig.1 B), 
as evident by a great increase in monosomes and sub- 
units with only a small fraction of polysomes con- 
sisting of 2-4 polyribosomes. At this concentration 
of pactamycin protein synthesis was inhibited by 89% 
(fig.I , legend). 
Fig.1, Sucrose gradients. Preparations of gradients and 517 
samples followed by scanning of profiles were as in section 2. 
(A) Polysomal profiles of diabetic rat and diabetic rat 
injected with insulin (5 U/100 g) 90 min before sacrifice. (B) 
Polysomal profiles of diabetic rats injected with insulin 
(5 UJlOO g) for 90 min with or without pactamycin (0.3 
mg/lOO g) 30 mm before insulin. At this pactamycin con- 
centration pactamycin inhibited protein synthesis by 89%. 
(C) Polysomal profiles of diabetic rats treated with insulin 
(5 U/100 g) for 60 min and cycloheximide at 1.0 mg/lOO g 
or 0.1 mgJ100 g before sacrifice. At 0.1 mg/lOO g protein 
synthesis was inhibited by 76%. All rats were given 5 g glu- 
coseJkg for 90 min before sacrifice. Arrows indicate position 
of monosomes. 
fering with initiation of protein synthesis as well. 
Therefore, at 0.1 mg/lOO g body wt cycloheximide 
was chosen and at this concentration protein synthesis 
was inhibited by 76% (fig.I , legend). 
Cycloheximide is known to interfere with elonga- 
tion of protein synthesis [ 131 causing an aggregation 
of ribosomes [ 161. A cycloheximide concentration 
was desired that would inhibit the elongation without 
interfering with initiation. As shown in fig.lC, the 
profile after cycloheximide treatment at 0.1 mg/ 100 g 
body wt was similar to that of insulin alone, while at 
1 .O mg/lOO g body wt the profile was deformed, 
monosome and subunit concentrations were increased 
as were smaller polysomes. This indicated that at this 
concentration, cycloheximide was probably inter- 
3.2. Translatable activity of poly(A)’ RNA 
Template activity of poly(A)* RNA for synthesis 
of total and released proteins as well as P-enolypruvate 
carboxykinase was quantitated in the wheat germ 
translation system and was proportionately linear with 
increasing amounts of poly(A)+ RNA (results not 
shown). As shown in table 1, insulin injected to dia- 
betic rats for 60 and 90 min, affected a marked 
decrease of the P-enolpyruvate carboxykinase mRNA, 
while the template activity for the synthesis of total 
I I 
n 3 6 9 Top 
b 
ml 
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Table 1 
Translatable activity of poly(A)+ RNA from diabetic rats treated with insulin, cycloheximide and 
pactamycin 
Treatment 
None 
Insulin 
Insulin 
Insulin and 
cycloheximide 
Insulin and 
cycloheximide 
Insulin and 
pactamycin 
Time (mm) after No. of [3H]Leucine incorporation (X 10m3) into 
insulin injection prep. 
Released Enzyme % dpm 
Protein (dpm) (dpm) in enzyme 
- 10 3570 2 200 6.55 -t 0.67 0.185 + 0.017 
60 5 3660 * 300 3.32 + 0.61 0.090 + 0.015 
90 6 436Ok 540 2.94 * 0.36 0.069 f 0.009 
60 4 4510 t 190 10.71 + 1.32 0.239 + 0.022 
90 7 4160 -t 500 7.39 * 0.81 0.182 f 0.020 
90 4 3750 f 400 6.13 + 0.34 0.170 + 0.016 
Diabetic rats were used as such or treated with insulin (5 U/l00 g) for the times indicated. Cyclohexi- 
mide (0.1 mg/lOO g body wt) and pactamycin (0.3 mg/lOO g body wt) were given 30 min prior to 
insulin. All rats were given 5 g glucose/kg at 90 min before sacrifice. Poly(A)+ RNA was isolated from 
the S17 fraction and translated in the wheat germ system as in section 2. The [3H]leucine incorporation 
into released proteins and P-enolpyruvate carboxykinase, and % incorporation in the enzyme, are 
expressed as dpm/3.6 fig poly(A)+ RNA, and are the means of the number of preparations * SEM 
proteins remained essentially the same. When express- 
ed as % incorporation it was evident that the insulin 
treatment for 60 and 90 min reduced translatable 
enzyme mRNA by -l/2 and 2/3rds, respectively. A 
t’/z of 55 min. was obtained for this decay which is in 
close agreement with previous calculations of 45 min 
in glucose-fed fasted rats [2,3], 40 min in cordycepin 
treated fasted rats [2], or 40 min in dBcAMP pre- 
treated Reuber H-35 cells when dBcAMP is removed 
]171. 
Pactamycin, (0.3 mg/lOO g body wt) given 30 min 
prior to insulin treatment of diabetic rats, inhibited 
the decay of P-enolpyruvate carboxykinase mRNA 
activity. Both [3H]leucine incorporation into released 
proteins and into the enzyme after pactamycin and 
insulin treatment were identical to that of untreated 
diabetic rats (table 1). 
Cycloheximide (an inhibitor of elongation) had a 
similar effect. Given at the times indicated in table 1, 
cycloheximide inhibited the insulin-mediated decay 
of P-enolpyruvate carboxykinase mRNA activity. 
These results suggested that either the decay of 
P-enolpyruvate carboxykinase mRNA activity was 
protein synthesis-dependent, or that the specific effect 
of insulin on that decay required protein synthesis. To 
distinguish between these two possibilities, we used 
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cordycepin, an inhibitor of poly(A)’ RNA 
appearance in the cytoplasm [ 181. As seen in table 2, 
cordycepin caused a rapid decline in the translatable 
mRNA for the enzyme when given to diabetic rats. 
By 90 min the template activity for the synthesis of 
the enzyme was 1/3rd that of untreated diabetic ani- 
mals (table l), while template activity for total pro- 
tein synthesis was unaffected. This effect of cordy- 
cepin was inhibited by either pactamycin or cyclo- 
heximide (given 30 min before cordycepin) with the 
mRNA activity for the synthesis of P-enolpyruvate 
carboxykinase remaining at the diabetic levels (or 
slightly above) (table 2). 
Cycloheximide and pactamycin, injected alone 
into diabetic rats for 2 h had little or no effect. When 
percent incorporations into enzyme were compared 
with those of the diabetic controls (table l), a slight 
Increase was noted. In order to determine if this 
increase was due to an accumulation of P-enolpyru- 
vate carboxykinase mRNA, cycloheximide was 
injected for 4 h and the translatable activity of total 
poly(A)’ RNA was determined. The results (not 
shown) indicated no additional increase in % incor- 
poration into the enzyme. Thus the possibility that 
cycloheximide (or pactamycin) induced an increase in 
translatable mRNA for the enzyme was unlikely. 
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Table 2 
Translatable activity of poly(A)’ RNA from diabetic rats treated with cordycepin, cycloheximide and 
pactamycin 
Treatment Time (min) injected No. of [3H]Leucine incorporation (X 10m3) into: 
before sacrifice prep. 
Released Enzyme % dpm 
protein (dpm) (dpm) in enzyme 
Cordycepin 90 6 3970 f 220 2.78 f 0.48 0.072 f 0.008 
Cycloheximide 120 4 3360 ? 290 8.18 f 0.98 0.251 k 0.041 
Cordycepin and 
cycloheximide 90 3 4430 f 630 9.93 f. 2.70 0.224 * 0.046 
Pactamycin 120 2 4200 11.79 0.281 
Cordycepin and 
pactamycin 90 3 433Ok430 8.88 + 0.84 0.205 + 0.006 
All rats were diabetic. Cycloheximide and pactamycin were injected alone or 30 min prior to cordycepin 
at concentrations as in table 1. Cordycepin was given at 1.5 mg/lOO g body wt. Isolation of poly(A)+ 
RNA and translation in the wheat germ system were as in section 2. Results are the mean dpm f SEM of 
[3H]leucine incorporation/3.6 pg poly(A)+ RNA 
4. Discussion and conclusion 
This evidence clearly demonstrates a rapid decay 
of translatable P-enolpyruvate carboxykinase mRNA 
initiated by insulin or cordycepin treatment of dia- 
betic rats. The rate at which the mRNA activity 
decreases, corresponds to reported rates at which the 
synthesis of the enzyme declines by similar treatment 
[l-3] indicating that the decrease in the rate of syn- 
thesis of Penolpyruvate carboxykinase reflects pre- 
dominantly the decrease in its functional mRNA. 
The effects of both insulin and cordycepin were 
completely inhibited by either cycloheximide or 
pactamycin, irrespective of the polysomal state or 
aggregation. While it is not known whether insulin 
accelerates the degradation or stops the synthesis of 
the mRNA, cordycepin is known for its inhibitory 
effect on the appearance of poly(A)’ RNA in the 
cytoplasm [18]. Thus, with cordycepin treatment, 
the observed decay of P-enolpyruvate carboxykinase 
mRNA represents the rate of inactivation in the 
absence of its replenishment. The inhibition of this 
decay by either pactamycin or cycloheximide, 
assuming no additional effects, indicates that the 
system for mRNA inactivation requires protein syn- 
thesis. Conceivably, this is because the turnover rate 
of this assumed inactivating system is very rapid. 
This system is evidently not unique for P-enolpy- 
ruvate carboxykinase mRNA. Recent evidence [ 191 
suggests that tyrosine amino transferase and trypto- 
phan oxygenase mRNAs (known for short half-lives) 
act similarly to P-enolpyruvate carboxykinase mRNA. 
Cycloheximide injected to rats preinduced with 
hydrocortisone caused increased translatable activity 
of both these mRNA whether free or bound to poly- 
somes [19]. Furthermore, cr-amanitin decreased these 
two mRNAs activities and its effect was prevented 
by cycloheximide, again implying that cyclohexi- 
mide stabilized the mRNAs in the absence of their 
synthesis. On the other hand no effect of cyclohexi- 
mide was noticable on albumin mRNA [ 191 which 
has been shown to be of a longer turnover rate [20] 
than P-enolpyruvate carboxykinase mRNA. That this 
effect of cycloheximide is a more general phenome- 
non is supported by the report that it affected an 
increase in the amount of poly(A)’ RNA in 3T6 cells 
in vitro [21]. 
From these findings the possible existence in rat 
liver of a general rapidly turning over inactivating 
system of mRNA is raised. Since various inhibitors of 
protein synthesis block the effect of this system, a 
peptide factor may be involved. Regulation of this 
system or factor would therefore be of great signifi- 
cance in regulating (cellular) translatable mRNAs. 
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